Cue Biopharma, Inc. announced the pricing of an underwritten public offering of its common stock and accompanying common stock warrants.
The aggregate gross proceeds of the offering are expected to be approximately $10 million.
The offering is expected to close on or about December 22, 2025.
Offering Details
35,714,286 shares of common stock and 17,857,143 shares through warrants are being offered at a price of $0.28 per share.
Underwriters
H.C. Wainwright & Co. is the sole book-running manager for the offering with Newbridge Securities Corporation as co-manager.
Option for Additional Shares
An option for up to 5,357,140 shares of common stock and/or warrants to purchase up to 2,678,570 shares has been granted to the underwriters.
- The pricing of the public offering indicates Cue Biopharma's strategy to raise funds for its clinical-stage biopharmaceutical developments.
- The immediate exercisability of the common stock warrants at a set price enhances investor interest in the offering.
Cue Biopharma's successful pricing of the public offering reflects investor confidence in the company's clinical advancements and growth potential in the biopharmaceutical sector.